Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark E Cooper

Showing results (111-120 of 399) with videos related to

Pageof 40
Sort By:
Journal of the American Society of Nephrology : JASN|July 23, 2003
Role of advanced glycation end products in diabetic nephropathyJosephine M Forbes, Mark E Cooper, Matthew D Oldfield, et al.
Archives of Internal Medicine|March 2, 2005
Anemia with impaired erythropoietin response in diabetic patientsMerlin C Thomas, Mark E Cooper, Con Tsalamandris, et al.
Journal of the American Society of Nephrology : JASN|December 25, 2003
Heparanase is involved in the pathogenesis of proteinuria as a result of glomerulonephritisVicki Levidiotis, Craig Freeman, Chris Tikellis, et al.
Journal of Hypertension|April 22, 2009
Eplerenone does not attenuate diabetes-associated atherosclerosisPhilip J W Koh, Audrey Koitka, Mark E Cooper, et al.
The Medical Journal of Australia|September 5, 2006
The assessment of kidney function by general practitioners in Australian patients with type 2 diabetes (NEFRON-2)Merlin C Thomas, Andrew J Weekes, Olivia J Broadley, et al.
Genes|April 9, 2014
Role of Cell Division Autoantigen 1 (CDA1) in Cell Proliferation and FibrosisBan-Hock Toh, Yugang Tu, Zemin Cao, et al.
Nephrology (Carlton, Vic.)|May 10, 2005
Heparanase inhibition reduces proteinuria in a model of accelerated anti-glomerular basement membrane antibody diseaseVicki Levidiotis, Craig Freeman, Chris Tikellis, et al.
Current Opinion in Pharmacology|July 23, 2013
Targeting advanced glycation endproducts and mitochondrial dysfunction in cardiovascular diseaseMicheal S Ward, Amelia K Fortheringham, Mark E Cooper, et al.
Current Pharmaceutical Design|November 17, 2004
Advanced glycation: how are we progressing to combat this web of sugar anomalies in diabetic nephropathyJosephine M Forbes, Vicki Thallas-Bonke, Mark E Cooper, et al.
Journal of Hypertension|January 12, 2005
Temporal renal expression of angiogenic growth factors and their receptors in experimental diabetes: role of the renin-angiotensin systemBishoy Rizkalla, Josephine M Forbes, Zemin Cao, et al.
Pageof 40

Showing results (111-120 of 399) with videos related to

Sort By:
Pageof 40
Journal of the American Society of Nephrology : JASN|July 23, 2003
Role of advanced glycation end products in diabetic nephropathyJosephine M Forbes, Mark E Cooper, Matthew D Oldfield, et al.
Archives of Internal Medicine|March 2, 2005
Anemia with impaired erythropoietin response in diabetic patientsMerlin C Thomas, Mark E Cooper, Con Tsalamandris, et al.
Journal of the American Society of Nephrology : JASN|December 25, 2003
Heparanase is involved in the pathogenesis of proteinuria as a result of glomerulonephritisVicki Levidiotis, Craig Freeman, Chris Tikellis, et al.
Journal of Hypertension|April 22, 2009
Eplerenone does not attenuate diabetes-associated atherosclerosisPhilip J W Koh, Audrey Koitka, Mark E Cooper, et al.
The Medical Journal of Australia|September 5, 2006
The assessment of kidney function by general practitioners in Australian patients with type 2 diabetes (NEFRON-2)Merlin C Thomas, Andrew J Weekes, Olivia J Broadley, et al.
Genes|April 9, 2014
Role of Cell Division Autoantigen 1 (CDA1) in Cell Proliferation and FibrosisBan-Hock Toh, Yugang Tu, Zemin Cao, et al.
Nephrology (Carlton, Vic.)|May 10, 2005
Heparanase inhibition reduces proteinuria in a model of accelerated anti-glomerular basement membrane antibody diseaseVicki Levidiotis, Craig Freeman, Chris Tikellis, et al.
Current Opinion in Pharmacology|July 23, 2013
Targeting advanced glycation endproducts and mitochondrial dysfunction in cardiovascular diseaseMicheal S Ward, Amelia K Fortheringham, Mark E Cooper, et al.
Current Pharmaceutical Design|November 17, 2004
Advanced glycation: how are we progressing to combat this web of sugar anomalies in diabetic nephropathyJosephine M Forbes, Vicki Thallas-Bonke, Mark E Cooper, et al.
Journal of Hypertension|January 12, 2005
Temporal renal expression of angiogenic growth factors and their receptors in experimental diabetes: role of the renin-angiotensin systemBishoy Rizkalla, Josephine M Forbes, Zemin Cao, et al.
Pageof 40